<DOC>
	<DOCNO>NCT01325181</DOCNO>
	<brief_summary>The purpose study compare efficacy safety intravitreal ranibizumab injection versus low-fluence PDT treatment chronic CSC .</brief_summary>
	<brief_title>Ranibizumab Versus Low-fluence Photodynamic Therapy Treatment Chronic Central Serous Chorioretinopathy</brief_title>
	<detailed_description>Central serous chorioretinopathy ( CSC ) characterize serous detachment neurosensory retina . The pathophysiology CSC certain various theory propose include impaired function retinal pigment epithelium ( RPE ) , choroidal ischemia choroidal hyperpermeability lead RPE damage . Acute CSC monofocal paucifocal change RPE usually show spontaneous resolution favorable visual outcome . Chronic CSC characterize multifocal diffuse decompensation RPE associate persistent detachment neurosensory retina . This might lead cystoid macular degeneration , foveal atrophy damage foveal photoreceptor layer , consequently result irreversible significant visual loss . Photodynamic therapy ( PDT ) propose treatment chronic CSC . Modified parameter PDT shorten time laser emission reduction total light energy suggest reduce irreversible damage induce conventional PDT . Recently , intravitreal injection antibody vascular endothelial growth factor ( VEGF ) propose new treatment option base effect anti-permeability . Several report demonstrate acceptable outcome intravitreal bevacizumab injection , one anti-VEGF agent . But clinical result ranibizumab report yet . The purpose study compare efficacy safety intravitreal ranibizumab injection versus low-fluence PDT treatment chronic CSC .</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>1. bestcorrected visual acuity ( BCVA ) 0.0 1.0 logarithm minimal angle resolution ( logMAR ) 2. presence subfoveal fluid persist 3 month optical coherence tomography ( OCT ) 3. presence leakage multifocal/diffuse RPE decompensation fluorescein angiography ( FA ) 4. choroidal vascular hyperpermeability abnormal dilation choroidal vasculature indocyanine angiography ( ICGA ) 1. previous treatment , laser photocoagulation , PDT , intravitreal injection steroid antiVEGF agent 2. evidence choroidal neovascularization 3. ocular disease could affect visual acuity 4. systemic steroid treatment previous 12 month 5. medium opacity cataract could interfere adequate acquisition OCT , FA ICGA image</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Chronic central serous chorioretinopathy</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Photodynamic therapy</keyword>
</DOC>